Progressive relapsing multiple sclerosis

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
BTK inhibitor 1 substance
Phase III: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

3 trials
  • Sanofi-Aventis Recherche & Developpement Commercial
    TERIFLUNOMIDE; TOLEBRUTINIB
    2023-503631-18-01 23 countries 2024 n=1,405
    Recruiting
  • Sanofi-Aventis Research & Development Commercial
    TERIFLUNOMIDE; TOLEBRUTINIB
    2023-503631-18-00 2 countries n=75
    Not authorised
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-512761-13-00 1 country 2022 n=60
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase III 1
Sanofi-Aventis Research & Development Commercial 1 Phase III 0
Assistance Publique Hopitaux De Paris Academic 1 Phase III 1
New trials by year
2022
1
2024
1
← All indication landscapes